Article
The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo.
Molecular cancer therapeutics - 1 Dec 2009
Douglas Mark, Lim Alice R, Porter James R, West Kip, Pink Melissa M, Ge Jie, Wylie Andrew A, Tibbits Thomas T, Biggs Kurtis, Curtis Michael, Palombella Vito J, Adams Julian, Fritz Christian C, Normant Emmanuel
Abstract excerpt
IPI-504, a water-soluble ansamycin analogue currently being investigated in clinical trials, is a potent inhibitor of the protein chaperone heat shock protein 90 (Hsp90). Inhibition of Hsp90 by IPI-504 triggers the degradation of important oncogenic client proteins. In cells, the free base of IPI-504 hydroquinone exists in a dynamic redox equilibrium with its corresponding quinone (17-AAG); the hydroquinone form...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.